for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Hisun Pharmaceutical Co., Ltd.

600267.SS

Latest Trade

10.31CNY

Change

-0.14(-1.34%)

Volume

9,713,583

Today's Range

10.24

 - 

10.52

52 Week Range

7.71

 - 

13.77

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
10.45
Open
10.43
Volume
9,713,583
3M AVG Volume
245.86
Today's High
10.52
Today's Low
10.24
52 Week High
13.77
52 Week Low
7.71
Shares Out (MIL)
965.53
Market Cap (MIL)
9,954.63
Forward P/E
103.10
Dividend (Yield %)
--

Latest Developments

More

PAG Highlander (Hk) To Invest 3.8 Bln Yuan In Zhejiang Hisun Pharma's Unit For 58% Stake

Zhejiang Hisun Pharmaceutical To Boost Unit's Capital, Sell Shares in Unit, Unit To Sell Property

Zhejiang Hisun Pharmaceutical To Sell 20.24% Stake In Pharmaceutical Technology Firm

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.

Industry

Major Drugs

Contact Info

No. 46, Waisha Road, Jiaojiang District

+86.576.88827809

http://www.hisunpharm.com

Executive Leadership

Guoping Jiang

Chairman of the Board, Acting President

Xiaohua Chen

Vice Chairman of the Board

Zhenying Zhang

Chief Financial Officer

Haibin Wang

Senior Vice President, Director

Shihong Cai

Vice President, Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

9.7K

2017

10.6K

2019(E)

11.5K
EPS (CNY)

2016

-0.100

2019(E)

0.100
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.95
Price To Book (MRQ)
1.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
173.70
LT Debt To Equity (MRQ)
61.10
Return on Investment (TTM)
-2.18
Return on Equity (TTM)
-1.14

Latest News

BRIEF-Zhejiang Hisun Pharmaceutical to swing to profit in FY 2017

* Sees to swing to net profit at 10 million yuan to 15 million yuan in FY 2017 versus net loss at 94.4 million yuan year ago

BRIEF-Zhejiang Hisun Pharmaceutical and unit obtain high-tech enterprise recognition and to enjoy tax preference

* Says it and unit were recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years

BRIEF-Zhejiang Hisun Pharma Adjusts Private Placement Plan, To Raise Up To 940.9 Mln Yuan

* SAYS IT ADJUSTS A-SHARE PRIVATE PLACEMENT PLAN, TO RAISE UP TO 940.9 MILLION YUAN ($144.66 million) Source text in Chinese: http://bit.ly/2zLTZwE Further company coverage: ($1 = 6.5040 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

* SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration

BRIEF-Zhejiang Hisun Pharmaceutical to issue up to 3.0 bln yuan commercial paper

* Says it plans to issue up to 3.0 billion yuan ($452.59 million) ultra-short commercial paper

BRIEF-Zhejiang Hisun Pharmaceutical unit says product gets FDA approval

* Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration

Pfizer exits China joint venture for generic drugs

Pfizer Inc <PFE.N> said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals <600267.SS> in 2012 to develop and market generic drugs.

BRIEF-Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration

BRIEF-Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV

* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction

BRIEF-Zhejiang Hisun Pharmaceutical plans to sell stake in Germany's INS

* Says it plans to sell its entire 21.05 percent stake in Germany's IMD Natural Solutions GmbH (INS)

BRIEF-Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval

* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration

BRIEF-Zhejiang Hisun Pharma cuts share issue size

* Says it cuts share issue size to 940.92 million yuan ($142.72 million) from 1.17 billion yuan previously

BRIEF- Zhejiang Hisun Pharmaceutical to set up pharmaceutical unit in Zhejiang

* Says it plans to set up a wholly owned pharmaceutical unit in Zhejiang, with registered capital of 10 million yuan

BRIEF-Zhejiang Hisun Pharmaceutical to pay FY 2016 annual div on July 7

* Says it will pay FY 2016 dividend to shareholders of record on July 6

BRIEF-Zhejiang Hisun Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration

BRIEF-Zhejiang Hisun Pharmaceutical receives administrative order

* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report

BRIEF-Zhejiang Hisun Pharmaceutical amends FY 2016 net profit outlook

* Says in the previous outlook, the company expected the net profit for FY 2016 to increase by 260 percent to 300 percent

BRIEF-Zhejiang Hisun Pharmaceutical gets approval for three drugs to enter clinical trials

* Says it got approval from China Food and Drug Administration to do clinical trials for three kinds of crud drugs

BRIEF-Zhejiang Hisun Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice(GMP) certificate from Zhejiang Food and Drug Administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up